Key statistics
As of last trade Eledon Pharmaceuticals Inc (2TK:FRA) traded at 2.36, -19.73% below its 52-week high of 2.94, set on May 20, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.36 |
---|---|
High | 2.36 |
Low | 2.36 |
Bid | 2.36 |
Offer | 2.46 |
Previous close | 2.32 |
Average volume | 61.11 |
---|---|
Shares outstanding | 39.66m |
Free float | 39.63m |
P/E (TTM) | -- |
Market cap | 104.69m USD |
EPS (TTM) | -2.52 USD |
Data delayed at least 15 minutes, as of Oct 10 2024 07:15 BST.
More ▼
Announcements
- Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
- Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients
- Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results
- Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection
- Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism
- Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
- Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
- Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
- Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
- Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement
More ▼